Draft:Atul Varadhachary

• Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. WikiEditorAndWriter (talk) 20:08, 3 July 2026 (UTC)

---

Atul Varadhachary (born c. 1963) is an Indian-American physician-scientist, biotechnology executive, and nonprofit leader. He is the managing partner of Fannin Partners (also known as Fannin Innovation Studio or Fannin). He previously served as president and chief operating officer of Agennix Inc. and worked as a management consultant at McKinsey & Company.

Early Life and Education

Varadhachary received his medical degree (M.B.B.S.) from Lokmanya Tilak Municipal Medical College (Sion Hospital) at the University of Mumbai. He subsequently earned a Ph.D. in physiology from the Johns Hopkins University School of Medicine and completed a postdoctoral fellowship in the Department of Biological Chemistry.

Johns Hopkins Postdoctoral Association

While a postdoctoral fellow at Johns Hopkins in the early 1990s, Varadhachary co-founded the Johns Hopkins University Postdoctoral Association (JHPDA) alongside Ora Weisz and others. Established in 1993, it was the first formal postdoctoral association in the United States.

Varadhachary served as the JHPDA’s founding president and led its initial efforts. The association was created to address concerns regarding postdoctoral working conditions, including disparities in compensation and institutional support, and to provide representation for postdoctoral fellows at the university. The JHPDA became a model for similar associations established at universities across the country.

Career

McKinsey & Company

After completing his postdoctoral training, Varadhachary joined McKinsey & Company as a management consultant, where he worked on healthcare strategy, innovation, and operations. Over approximately seven years, he rose to the level of senior engagement manager.

Agennix

In 2001, Varadhachary became president and chief operating officer of Agennix Inc., a Houston-based biotechnology company developing talactoferrin alfa, an immunotherapy candidate for cancer treatment.[5] He led the program from preclinical development through global Phase III clinical trials in non-small-cell lung cancer. He co-authored peer-reviewed clinical trial publications on talactoferrin alfa, including a randomized phase II study published in the Journal of Clinical Oncology and a combination therapy study published in the Journal of Thoracic Oncology. Agennix was later acquired by a German biotechnology company.

Fannin Innovation Studio

In 2013, Varadhachary co-founded Fannin Innovation Studio with Leo Linbeck III and Mark Worscheh, a Houston-based organization focused on commercializing life sciences technologies originating from academic institutions, including the Texas Medical Center. He served as a managing partner of the organization.

Fannin Innovation Studio was established to support the development and commercialization of biomedical technologies emerging from academic research. The organization employs a shared management model in which a central team provides operational and strategic support across multiple portfolio companies.

During Varadhachary's tenure, Fannin supported the development of companies in areas including cardiovascular disease, oncology, respiratory disease, and diagnostics. Portfolio companies associated with the organization have included Procyrion, Pulmotect, Allterum Therapeutics, and Brevitest Technologies.

The organization has also operated training and mentorship programs focused on life sciences entrepreneurship and technology commercialization.

Pratham and Global Health

During a leave of absence from McKinsey in 1998–1999, Varadhachary and his wife, Gauri Rajani Varadhachary, co-founded Pratham Health in Mumbai. The program focused on child health interventions and was later spun off as the Niramaya Health Foundation. He subsequently co-founded Pratham USA and served as its president from 2008 to 2013, during which time the organization received the Times of India Social Impact Award for International Contribution to India.

Academic and Civil Roles

Varadhachary has held adjunct faculty appointments at Rice University’s Jones Graduate School of Business (2002–2023), Baylor College of Medicine (2003–2013), and the University of Texas School of Public Health (2014–2025). He has served on advisory boards and committees including the Cancer Prevention and Research Institute of Texas (CPRIT), BioHouston, the Greater Houston Partnership’s Healthcare Advisory Committee, and the Harris Health System Board of Managers. He has served as president of the Indo-American Chamber of Commerce and TiE Houston.

Personal Life

Varadhachary’s wife, Gauri Varadhachary, was a clinical professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center. She authored a widely cited review of cancer of unknown primary for the New England Journal of Medicine and received the Melvin L. Samuels Award for excellence in patient care. She died in 2021 at the age of 52.

Selected Publications

Varadhachary A, et al. “Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy.” International Journal of Cancer. 2004;111(3):398–403.

Spadaro M, Curcio C, Varadhachary A, et al. “Requirement for IFN-γ, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors.” Cancer Research. 2007;67(13):6425–32.

de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ. “Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses.” Journal of Immunology. 2008;180(10):6868–76.

Parikh PM, Vaid A, et al., Varadhachary A. “Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.” Journal of Clinical Oncology. 2011;29(31):4129–36.